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Objective: The impact of early hormonal contraception (HC) exposure during breastfeeding 
on child growth and pubertal and behavioural development was assessed using data from the 
Avon Longitudinal Study of Parents and Children (Avon study). 
 
Study design: The Avon study is a prospective cohort study designed to identify 
environmental factors affecting child health and development (n=14,541; delivery dates: 1 
April 1991-31 December 1992). This secondary analysis was restricted to breastfed singleton 
infants. The main independent predictor variable was HC exposure during the first 8 weeks 
postpartum. Growth variables were changes from baseline in weight and height at ages 2 and 
4 years. Behavioural variables were assessed at age 47 months. Pubertal development was 
evaluated between ages 8- and 16-years using Tanner scales.  
 
Results: 9,508 children were breastfed during the first 4 weeks postpartum; 8,927 had 
complete data for breastfeeding and HC exposure. Multivariate analyses demonstrated no 
difference in growth outcome variables between breastfed infants exposed to HC and those 
who were not. Similarly, no differences in behavioural problems or pubertal development 
were observed between the two groups. 
 
Conclusions: Early HC exposure during breastfeeding did not appear to influence negatively 
child growth and development. Limitations include short-term exposure to HC, the 
discrepancy between the timepoints when HC intake and breastfeeding were measured and 
the missing data, particularly regarding growth measurements Further clinical studies are 
required to confirm this lack of negative impact. 
 
Implications statement:  
Guidance on the use of HC during breastfeeding remains controversial; however, the Avon 
study did not detect any signal to suggest that early exposure to HC via breastfeeding has a 






Short birth intervals following childbirth is an important global public health issue. Data from 
national household surveys indicate that, among other factors, an interval of <24 months 
between births is associated with elevated child mortality rates [1]. Postpartum contraception 
may improve maternal health and decrease child mortality rates by spacing births. While 
breastfeeding provides a form of contraception, many women do not breastfeed exclusively, 
despite World Health Organization (WHO) recommendations [2]. A 2010 UK survey showed 
that 81% of babies in the UK were breastfed at birth; however, only 13-24% of babies were 
exclusively breastfed 6 weeks post-childbirth [3]. 
 
Since partial breastfeeding alone cannot provide adequate contraception, a safe and easy-to-
use contraceptive method may improve both maternal and child health by spacing the births. 
Hormonal contraception (HC) can be used postpartum, but the timing of initiation and type of 
contraceptives remains the subject of ongoing debate, particularly regarding potential adverse 
effects on breast milk production that will impact baby growth. 
 
Two types of HC are typically used by lactating women: combined HCs (CHC) and 
progestogen-only contraceptives (POC) [4]. CHCs are often preferred due to their familiarity, 
ease of use, immediate return to fertility upon cessation, and effectiveness. [5] Indeed, some 
women stop breastfeeding early in order to initiate CHCs [2;6]. POCs are an alternative to 
CHCs and have been shown to be safe and effective for nearly all women, irrespective of age, 
including those who are breastfeeding, have or have not had children, are smokers, or have 
anaemia. [7]. However, side effects (e.g. acne, breast tenderness and enlargement, issues with 
libido, mood changes, headache and migraine, nausea or vomiting, and ovarian cysts) occur 
more often with POCs than with CHCs. In addition, POCs need to be administered at the 
same time every day for optimal efficacy and are perceived to be less effective than CHCs. 
Together, this means that CHCs are preferred over POCs. 
 
Ideally, the HC chosen by lactating women should not interfere with lactation and infant 
growth and should not be detected in the breast milk. The WHO recommends the use of HC 
during breastfeeding [2;4;8]: POCs and progestin implants are recommended even in the first 






Although POCs are the recommended HC for lactating women, particularly in the first 6 
months postpartum, some users express concerns about its use, including potential adverse 
effects on breastfeeding performance, maternal health, and infant health or growth. Although 
several studies have demonstrated that POCs do not compromise a mother's breastfeeding 
ability [10-12], the majority of these studies were observational, lacked clear definitions of 
breastfeeding, and failed to control for confounders [12]. The impact of POCs on child health 
and development beyond the first year postpartum has not been established and the effects on 
brain development in new-borns are not well documented. CHCs have been shown to impair 
lactation by inhibiting prolactin [8], and there are concerns about the passage of exogenous 
oestrogens in breast milk when using CHCs [10]. The safety and optimal timing of HC 
initiation during lactation remain challenging, especially in the implementation of existing 
guidance [9]. 
 
The lack of adverse effects of HCs on infant growth reported in systematic reviews neither 
supports nor contradicts previous WHO recommendations regarding use of POCs during the 
first 6 weeks postpartum [10;13]. Consequently, decisions regarding the initiation of HC must 
be made on other grounds. The WHO convened key experts in the field for a meeting in 
October 2008 [4], during which a key evidence gap was identified: 
• Clinical outcomes for infants exposed to POCs via breastfeeding, particularly early 
exposure (i.e. first 6 weeks) to progestogens, using sensitive measures of behavioural 
development.  
 
1.1 Objectives of the current analysis 
Using data from the Avon Longitudinal Study of Parents and Children (Avon study), an 
existing long-term cohort of women and their babies, the main objective of this analysis was 
to assess the impact of early HC exposure during breastfeeding on child growth, pubertal and 
behavioural development. 
 
2. MATERIALS AND METHODS 
2.1 The Avon study 
The Avon study was a prospective cohort study to identify pre- and post-natal 
environmental factors that may affect the development, health and wellbeing of children 
[14;15]. A total of 14,541 pregnant women in three health districts of Avon, UK, with 




study. Among these, 14,062 had live births and 13,988 infants were alive at 1 year. The 
sub-population of interest in the present study was breastfed singleton infants. Data were 
derived from previously collected self-completed questionnaires. The study website 
contains details of all the data that are available through a fully searchable data dictionary 
[16]. 
 
Ethical approval for the main study was obtained from the Avon study Ethics and Law 
Committee and the Local Research Ethics Committees. 
 
2.2  Predictor variables 
The main predictor variable was HC exposure in the baby as measured at 8 weeks after 
birth, hereafter termed “Breastfeeding & HC”. The variable “Breastfeeding & HC” 
differentiates the subjects into “exposed” vs “not exposed” in our study. We excluded 
non-breastfed babies from all analyses. 
 
2.3  Outcome variables 
 
2.3.1  Growth variables 
The primary outcomes of our analysis were changes from baseline in weight and height at 
2 years and 4 years of age, all of which represent validated measures to assess infant 
growth and development [17]. Birth weight and height data were previously obtained from 
obstetric records. Birth height (crown to heel) was measured using a Harpenden 
neonatometer (Holtain Ltd., Crymych, United Kingdom). A sub-group of the Avon study 
cohort, Children in Focus (CIF) [17], included 1,335 term (gestation 37-42 weeks) 
singletons who were measured at birth and on successive occasions until the age of 5 years 
(at 4, 8, 12, 25, 31, 37, 43, 49 and 61 months). The CIF is the only sub-group with 
continual growth data during the follow-up period (FU; measurements <7 years of age).  
 
Additional weight and height data were available from questionnaires completed by the 
mother at pre-determined timepoints.   
 
2.3.2  Behavioural variables  
Behavioural variables were assessed and scored using the Strengths and Difficulties 




child at age 47 months (~4 years). The 25-item SDQ comprises five subscales (five items per 
subscale): prosocial, hyperactivity, emotional symptoms, conduct problems, and peer 
problems scores. The total difficulties score is derived from the sum of the last four scores. 
Responses for each item within a subscale are scored from 0 to 2, resulting in scores of 0 to 
10 for each subscale. The total difficulties score ranges from 0 to 40. High scores denote 
increased behavioural problems, except for the prosocial subscale, which is a reverse score. 
Behavioural problems were defined as the highest (or the lowest for prosocial behaviour) 
tertile for each subscale and the total difficulties score.  
 
2.3.3  Pubertal development variables 
Pubertal development was assessed by the Avon study using eight questionnaires, 
administered to children at 97, 116, 128, 140, 157, 175, 186 and 192 months corresponding to 
8.1, 9.7, 10.7, 11.7, 13.1, 14.6, 15.5 and 16 years of age. Outcomes of interest included the 
development of breasts, pubic hair and menstruation for girls and development of genitals 
and pubic hair for boys [21;22]. These are recognised variables in paediatric endocrinology to 
define puberty [21-23]. Pubertal stage was defined using Tanner scales.  
 
2.5  Statistical analyses 
This study analysed the impact of HC exposure during the first 8 weeks postpartum on child 
growth and behavioural outcomes, controlling for potential confounders including maternal 
smoking and alcohol consumption during pregnancy (Appendix). Sample sizes for each 
analysis are shown in Figure 1.  
 
Statistical analyses were performed using SPSS version 18 (SPSS Inc, Chicago) [24;25]. 
Multiple regression analyses of each outcome variable, including birth hospital, as a random 
effect were performed using the mixed-effects model. As the clustering effect of hospitals 
was non-significant, results of the fixed-effect model are presented. The impact of time on 
mean weight and height measured at baseline, 2 years, and 4 years was assessed using the 
GLM-repeated measures models, excluding random effects [24;25]. A sensitivity analysis 
was conducted for the growth variables with multiple imputation for missing values. 
 
Logistic regression analyses were conducted to assess the impact of baby HC exposure 
during the first 8 weeks postpartum on each of the six SDQ scores, adjusting for confounding 




significantly to the prediction of the outcome variable in the model were identified and 
excluded using the stepwise backward method. 
 
A survival analysis was conducted in children whose first two questionnaires were completed 
(aged 8.1 and 9.7 years). Five life-table survival analyses were created for each outcome. The 
main events of interest were attainment of Tanner stage 3 and appearance of menses. 
Discontinuation from the study was defined as two missing consecutive FU visits or failure to 
reach Tanner stage 3 by the time the sixth FU questionnaire was administered. The 
Wilcoxon-Gehan test was applied to compare survival curves. 
 
2.6  Subgroup analyses 
As child growth at 2 and 4 years is sex-specific, subgroup analyses according to sex were 
conducted. All growth-related results are presented separately for males and females. The 
interaction between Breastfeeding & HC and sex was not assessed. Analyses were restricted 
to subjects with complete data for the relevant variables involved.  
 
3. RESULTS 
Breastfeeding information was available for 12,047 of the 14,273 singleton pregnancies 
enrolled (84%) Figure 1. Among these, 9,508 (79%) were breastfed, either partially or 
exclusively, during the first 4 weeks postpartum and considered for analysis. Overall, 8,927 
children were breastfed and had information on HC exposure. There was a significant drop-
out in height and weight measurements, particularly at 4 years FU, which affected the 
precision of the corresponding estimates. In particular, the multivariate analysis included 
1,905 and 1,524 children in the final model for weight and height differences, respectively, at 
2 years. Logistic regression analysis of behavioural variables was possible for 6,892 subjects 
with complete data (77% of subjects with Breastfeeding & HC data).  
 
3.1  Growth outcomes 
The multivariate analysis demonstrated no difference in adjusted mean weight and height 
changes from baseline at 2 and 4 years between infants exposed to HC via breastfeeding and 
those who were not (Table 1). Adjusted means were estimated and controlled for covariates 





3.2  Behavioural assessment 
No differences in behavioural problems were observed between the two groups, as assessed 
using the SDQ questionnaire at 47 months (Table 2). The odds ratio of having behavioural 
problems in the prosocial score (lower tertile) in babies exposed to HC was 0.95, (CI 0.82-
1.10; p=0.45), after adjustment for all other confounding variables. 
 
The capacity of the model to predict whether a subject would belong to the higher tertile for 
the other subscales (i.e. have behavioural problems) varied between 58 and 67% (Table 2). 
The overall predictive power of the total score was 66%. The two groups were comparable 
for each of the five behavioural scores. 
 
3.3  Pubertal development 
Survival analysis results for pubertal development are presented in Figures 2 and 3 and in 
Table 3. The percentage of subjects with pubertal development data available was low, 
mainly due to missing data, and varied from 18% for development of pubic hair in boys to 
23.8% for development of pubic hair and menses in girls. In this subgroup, there was no 
evidence to suggest any differences between HC exposure groups for any of the pubertal 
development outcomes assessed. 
 
4. DISCUSSION 
In this study, no differences in growth, behaviour and pubertal development were observed 
between babies exposed to HC via breastfeeding and those who were not. These results are 
consistent with previous data showing no adverse effects with using HCs (particularly POCs) 
in the first 6 weeks postpartum [10;11]. However, most prior studies evaluated POC use 
towards the end of the first 6 weeks postpartum, had relatively short FU periods, and assessed 
short-term endpoints. Therefore, the long-term impact of HC exposure during breastfeeding 
in the initial few weeks post-childbirth on child growth or behaviour were not evaluated. The 
current analysis focused on early HC exposure (the first 4-8 weeks postpartum) and was 
based on the assessment of clinically-relevant outcomes, including growth, behavioural and 
pubertal variables. 
 
4.1  Strengths and limitations of the Avon study cohort 
The Avon study cohort is widely considered representative of the UK population. The main 




quantity of detailed longitudinal data collected. Psychological and environmental factors, 
considered as potential confounders in this analysis, were a main focus in the Avon study. 
 
Only children from multiple pregnancies and those who were not breastfed were excluded 
from our analysis. All other groups, such as children with severe diseases or malformations 
and pre-term infants, were included. Our study population could be representative of the 
global population.  
 
A negative impact of HC exposure via breastfeeding on child growth in the first years of life 
was not expected, based on the results of previous studies. However, a key evidence gap 
identified in the expert meeting in 2008 was the impact of early HC exposure on child 
behaviour. This analysis attempts to fill this gap and to our knowledge all outcome variables 
investigated in this study were clinically relevant and related to child development and 
behaviour. Moreover, medium- and long-term outcomes of pubertal development were 
investigated. 
 
One potential source of bias in our study is the discrepancy between the timepoints when HC 
intake and breastfeeding were measured. We present here the analysis for the data collected 
at 4 weeks for breastfeeding and 8 weeks for the use of HC. Data was also collected at 6 
months for breastfeeding and at 8 months for the use of HC; a separate analysis showed 
similar results to our current findings (data not shown). This indicates that our analysis was 
not affected by the discrepancy in data collection. Another limiting factor of our study is the 
proportion of subjects with missing data, particularly growth measurements (Figure 1). As 
subjects with missing data for outcome variables or potential confounders were excluded 
from the respective analysis, less than half the cohort was used in the main analysis. The 
multiple imputation analysis showed that the non-significant results for the differences 
between the groups exposed to HC and not exposed to HC are stable (replicated) across the 
different imputed data sets. Therefore, we are confident that these results are not biased by 
the potential effect of the missing data.  Furthermore, birth weight and length measurements 
were obtained from obstetric records or based on measurements taken by trained Avon study 
staff, suggesting that the potential for recall bias in these measurements is low. 
 
Childhood behavioural problems were ascertained by parental completion of the SDQ. It is 




association between behavioural problems and HC exposure. The behavioural data presented 
here are consistent with those in previous studies, including one study that used similar 
statistical methodology [20;28]. However, behaviour in our analysis was evaluated at an 
earlier age than that considered reliable from a previous study (4 vs 7 years of age) and, 
therefore, may be considered less robust [20]. 
 
We adjusted for numerous confounders, including maternal smoking and alcohol 
consumption during pregnancy; however, the presence of residual confounding factors cannot 
be completely ruled out. Although the prediction capacity of our model may have been 
enhanced with the inclusion of additional confounders, this was outside the scope of the 
analysis. 
 
Distinguishing the effects of POC versus CHC was an important initial objective of this 
analysis; however, the data collection questionnaire used at 8 weeks postpartum did not 
require respondents to specify the type of contraception used. Also, a large proportion of 
subjects had missing data (76.7%), rendering it impossible to determine the effects of POC 
versus CHC in our study. Nevertheless, in the sample of subjects where type of contraception 
could be discerned, 28.8% of women used CHC and 44.8% used POC, with the remaining 
26.4% receiving an unidentified type of contraception. 
 
5. CONCLUSIONS  
No differences in the evolution of weight and height of the child at 2 and 4 years were found 
between babies exposed to HCs via breastfeeding and those who were not. Additionally, HC 
exposure did not appear to adversely affect child behaviour or pubertal development. 
However, the Breastfeeding & HC variable was identified as a weak predictor of behavioural 
outcomes. Although our study did not find any evidence to support a negative impact of HC 
use during breastfeeding on the child’s growth and development, the possibility cannot be 
completely excluded.  
 
6. APPENDIX 
6.1 Potential confounders 
Data on potential confounders were available from self-report postal questionnaires 
completed by the mother during pregnancy and following birth. Potential confounder 




maternal and partner smoking and alcohol consumption in the first 3 months and last 2 
months of pregnancy, and at 8 weeks post-birth; child ethnicity; outcome of previous 
pregnancy; fertility history; use of HC during pregnancy; sexual abuse of the mother; 
socioeconomic markers (maternal and partner education); child health at 4 weeks; and 
continuous parameters (mother's height, mother's age at menarche, mother's pre-pregnancy 
weight, and height of biological father).  
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